Pharmaceuticals - Community Register


Community register of medicinal products for human use


Product information

Invented name: Tafinlar   
Auth. number : EU/1/13/865
ATC: Anatomical main group: L - Antineoplastic and immunomodulating agents
Therapeutic subgroup: L01 - Cytostatics
Pharmacological subgroup: L01X - Other cytostatics
Chemical subgroup: L01XE - Protein kinase inhibitors
Chemical substance: L01XE23 - Dabrafenib
(See WHO ATC Index)
Indication: Monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Marketing Authorisation Holder: GlaxoSmithKline Trading Services Limited
Currabinny, Carrigaline, County Cork, Ireland

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.


European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
29/08/2013 Centralised - Authorisation EMEA/H/C/2604 (2013)5604 of 26/08/2013
20/02/2014 Centralised - Variation EMEA/H/C/2604/II/2/G
05/06/2014 Centralised - Variation EMEA/H/C/2604/IG/442
24/07/2014 Centralised - Variation EMEA/H/C/2604/II/1/G